Tag Archives: 436 patients consisting of 836 patients in a fully cross-validated training group and independent testing group of 600 patients. The study describes the

miR Scientific presents breakthrough new data on the miR Scientific Sentinel™ tests for the detection and classification of prostate cancer in urinary exosomes

exosomes

Dr. Laurence Klotz M.D., FRCSC, CM, the Chief Medical Officer of miR Scientific LLC, presents the results of the recently completed Case-Control validation study of 1,436 patients consisting of 836 patients in a fully cross-validated training group and independent testing group of ...

Read More »